Haemonetics
258 hedge funds and large institutions have $3.36B invested in Haemonetics in 2021 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 102 increasing their positions, 80 reducing their positions, and 87 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 80
1.88% more ownership
Funds ownership: 97.6% → 99.49% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less call options, than puts
Call options by funds: $20.6M | Put options by funds: $21.3M
13% less funds holding
Funds holding: 296 → 258 (-38)
39% less capital invested
Capital invested by funds: $5.49B → $3.36B (-$2.13B)
39% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 87
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$160M |
| 2 |
BlackRock
New York
|
+$83.6M |
| 3 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
+$67.5M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$66.9M |
| 5 |
Neuberger Berman Group
New York
|
+$65.3M |
Top Sellers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$250M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$159M |
| 3 |
O
OrbiMed
New York
|
-$94.6M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$69M |
| 5 |
CG
Carmignac Gestion
Paris,
France
|
-$48.9M |
HAE Hedge Fund Activity: Q2 2021 in Review
258 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2021, worth a combined $3.36B — down 39% from $5.49B a quarter earlier.
Sellers outnumbered buyers: 87 funds closed out of HAE and 53 opened new positions — a net loss of 34 holders — while 80 trimmed existing stakes and 102 added.
The largest buyer was Wellington Management Group, adding an estimated $160M. The largest seller was Capital Research Global Investors, cutting an estimated $250M.
- 258 institutional investors held Haemonetics (HAE) as of Q2 2021, down from 296 in Q1 2021.
- Funds reported $3.36B of Haemonetics stock for Q2 2021, down 39% quarter-over-quarter.
- 53 funds opened new Haemonetics positions in Q2 2021 and 87 closed out, a net change of -34 holders.
- The largest Haemonetics buyer in Q2 2021 was Wellington Management Group, an estimated $160M added.
- The largest Haemonetics seller in Q2 2021 was Capital Research Global Investors, an estimated $250M sold.
Based on aggregated 13F filings for Q2 2021.